Immunotherapy in second-line monotherapy or in first-line as monotherapy in patients with PD-L1 > 50% and in combination with front-line chemotherapy in patients with PD-L1 < 50% changed the history of patients with advanced non-NSCLC non-oncogene addicted with 5-year OS of 20% in non-selected patients, and up to 50% in patients with high PD-L1 expression [5,147]. Here, CD274 is linked to non-small cell lung carcinoma.